JPWO2020239568A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020239568A5
JPWO2020239568A5 JP2021569359A JP2021569359A JPWO2020239568A5 JP WO2020239568 A5 JPWO2020239568 A5 JP WO2020239568A5 JP 2021569359 A JP2021569359 A JP 2021569359A JP 2021569359 A JP2021569359 A JP 2021569359A JP WO2020239568 A5 JPWO2020239568 A5 JP WO2020239568A5
Authority
JP
Japan
Prior art keywords
etoh
methanesulfonylphenoxy
fluoro
propyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021569359A
Other languages
Japanese (ja)
Other versions
JP2022533433A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/064046 external-priority patent/WO2020239568A1/en
Publication of JP2022533433A publication Critical patent/JP2022533433A/en
Publication of JPWO2020239568A5 publication Critical patent/JPWO2020239568A5/ja
Pending legal-status Critical Current

Links

Description

[2-(3-フルオロ-5-メタンスルホニルフェノキシ)エチル](プロピル)アミンヘミ-L-酒石酸塩の合成:
実施例2からの[2-(3-フルオロ-5-メタンスルホニルフェノキシ)エチル](プロピル)アミンのEtOH溶液(推定量:24.5g、88.9mmol)を、濃度が0.40MになるまでEtOHで希釈した。水(20mL)中のL-酒石酸(6.81g、45.4mmol)の溶液を添加した。形成されたスラリーを、還流温度に加熱し、追加量のEtOH(50mL)および水(5mL)を添加した。固体がすべて溶解するまで加熱を続けた。混合物を室温に冷却させた後、形成されたスラリーを室温で一晩、次いで5~10℃で5時間撹拌した。沈殿物を濾過により単離し、濾過ケーキをEtOH(3×35mL)で洗浄した。生成物を、そこから空気を抜くことで20分間乾燥した。99.9%のLC純度を有する固体として29.9g(96%)の[2-(3-フルオロ-5-メタンスルホニルフェノキシ)エチル](プロピル)アミンヘミ-L-酒石酸塩を得た。H NMR(400MHz,DMSO-d):δ 0.89(t,3H),1.55(m,2H),2.74(t,2H),3.13(t,2H),3.28(s,3H),3.89(s,1H),4.27(t,2H),7.25(m,1H),7.3-7.4(m,2H)。
Synthesis of [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine hemi-L-tartrate:
A solution of [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine from Example 2 in EtOH (assumed: 24.5 g, 88.9 mmol) was added to a concentration of 0.40 M. Diluted with EtOH. A solution of L-tartaric acid (6.81 g, 45.4 mmol) in water (20 mL) was added. The slurry formed was heated to reflux and additional EtOH (50 mL) and water (5 mL) were added. Heating was continued until all solids dissolved. After allowing the mixture to cool to room temperature, the slurry formed was stirred at room temperature overnight and then at 5-10° C. for 5 hours. The precipitate was isolated by filtration and the filter cake was washed with EtOH (3 x 35 mL). The product was dried for 20 minutes by removing air from it. Obtained 29.9 g (96%) of [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine hemi-L-tartrate as a solid with an LC purity of 99.9%. 1 H NMR (400 MHz, DMSO-d 6 ): δ 0.89 (t, 3H), 1.55 (m, 2H), 2.74 (t, 2H), 3.13 (t, 2H), 3 .28 (s, 3H), 3.89 (s, 1H), 4.27 (t, 2H), 7.25 (m, 1H), 7.3-7.4 (m, 2H).

JP2021569359A 2019-05-24 2020-05-20 Pharmaceutically acceptable salts of [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine and uses thereof Pending JP2022533433A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19176514 2019-05-24
EP19176514.8 2019-05-24
EP20166361.4 2020-03-27
EP20166361 2020-03-27
PCT/EP2020/064046 WO2020239568A1 (en) 2019-05-24 2020-05-20 Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Publications (2)

Publication Number Publication Date
JP2022533433A JP2022533433A (en) 2022-07-22
JPWO2020239568A5 true JPWO2020239568A5 (en) 2023-05-29

Family

ID=70682855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569359A Pending JP2022533433A (en) 2019-05-24 2020-05-20 Pharmaceutically acceptable salts of [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine and uses thereof

Country Status (19)

Country Link
US (1) US20220267262A1 (en)
EP (2) EP4292653A3 (en)
JP (1) JP2022533433A (en)
KR (1) KR20220011638A (en)
CN (1) CN113853369A (en)
AU (1) AU2020286003A1 (en)
BR (1) BR112021023563A2 (en)
CA (1) CA3140805A1 (en)
CL (1) CL2021003115A1 (en)
CO (1) CO2021016556A2 (en)
DK (1) DK3976581T3 (en)
ES (1) ES2970361T3 (en)
FI (1) FI3976581T3 (en)
IL (1) IL288271A (en)
JO (1) JOP20210312A1 (en)
MX (1) MX2021014271A (en)
PT (1) PT3976581T (en)
SG (1) SG11202112165QA (en)
WO (1) WO2020239568A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4243801A1 (en) * 2020-11-10 2023-09-20 Integrative Research Laboratories Sweden AB [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias
WO2024042540A1 (en) * 2022-08-24 2024-02-29 Alkem Laboratories Limited Mesdopetam compositions
WO2024062344A1 (en) 2022-09-21 2024-03-28 Assia Chemical Industries Ltd. Solid state forms of mesdopetam and salts therof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904723D0 (en) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
AU2006259891A1 (en) 2005-06-23 2006-12-28 Albireo Ab New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
EP2155668A2 (en) * 2007-06-08 2010-02-24 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-ý4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl¨-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
PL2699543T3 (en) * 2011-04-19 2016-10-31 Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission
MD3649124T2 (en) * 2017-08-07 2021-07-31 Suven Life Sciences Ltd Fluoropiperidine compounds as pure 5-HT6 receptor antagonists

Similar Documents

Publication Publication Date Title
JP2012500819A5 (en)
JP2009503034A (en) Process for producing 7H-pyrrolo [2,3-d] pyrimidine derivative
JP2023154056A (en) Method of preparing epalrestat
JP2010510253A5 (en)
JP2011503053A (en) Process for producing 2-hydroxy-5-phenylalkylaminobenzoic acid derivatives and salts thereof
AU731835B2 (en) Method of manufacturing sertindole
JP7379470B2 (en) Method of preparation of lenvatinib
JPWO2020239568A5 (en)
TW212181B (en)
JP4770826B2 (en) Method for producing 2-oxindole derivatives
JPS5821658B2 (en) Enkisei Oxaginseng Ryounoseihou
JP6228210B2 (en) Method for purifying fluvoxamine free base and method for producing high purity fluvoxamine maleate using the same
JP5757665B2 (en) A novel method for preparing imatinib base
JP2020533284A (en) Gadobutrol intermediate and method for producing gadobutrol using it
JP2010502682A5 (en)
JP6284942B2 (en) Improved method for preparing 2-amino-5,8-dimethoxy [1,2,4] triazolo [1,5-c] pyrimidine from 4-amino-2,5-dimethoxypyrimidine
JP4433365B2 (en) Process for producing 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutanamide
WO2016035405A1 (en) Azo dye composition and method for producing same
CN107011322A (en) A kind of high-purity dehydrophenylahistin class compound prepares purification process
JPS6363658A (en) Manufacture of substituted indolinone derivative
JP5087059B2 (en) Process for producing 4- (2-methyl-1-imidazolyl) -2,2-diphenylbutanamide
JP4078328B2 (en) Method for producing 2-oxindole derivatives
JPH072742A (en) New production method of 4-amino-3-methyl-n-ethyl-n-(beta-hydroxyethyl)aniline sulfuric acid salt
CN117126108A (en) Preparation method of Ensitrelvir intermediate
CN113480523A (en) Preparation method of pimobendan